A mouse monoclonal antibody against dengue virus type 1 mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity

Journal of Virology

Volumn 87, Issue 23, 2013, Pages 12828-12837

  Yamanaka, Atsushi ^a,b,c   Kotaki, Tomohiro ^b,c,d   Konishi, Eiji ^a,b,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AIRLANGGA UNIVERSITY   (Indonesia)

^d KOBE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FC RECEPTOR IIA; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3H12; MONOCLONAL ANTIBODY 7F4; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANTIBODY ENGINEERING; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 1; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; MICE; MICE, INBRED BALB C; VIRAL ENVELOPE PROTEINS;

EID: 84887157759     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01874-13     Document Type: Article

References (63)

1. Lindenbach BD, Thiel HJ, Rice CM. 2007. Flaviviridae:the viruses and their replication, p 1101-1152. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Gubler DJ, Kuno G, Markoff L. 2007. Flavivirus, p 1153-1252. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Halstead SB. 2007. Dengue. Lancet 370:1644-1652.
4. World Health Organization. November 2012. Fact sheet no. 117. Dengue and severe dengue. http://www.who.int/mediacentre/factsheets/fs117/en /index.html.
5. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Nisalak A. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9.
6. Halstead SB, O'Rourke EJ. 1977. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265:739-741.
7. Halstead SB. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60:421-467.
8. Pierson TC, Diamond MS. 2008. Molecular mechanisms of antibodymediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10:e12. doi:10.1017/S1462399408000665.
9. Heinz FX, Stiasny K. 2012. Flaviviruses and their antigenic structure. J. Clin. Virol. 55:289-295.
10. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus:implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
11. Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 100:6986-6991.
12. Crill WD, Roehrig JT. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773.
13. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7:e1002111. doi:10.1371 /journal.ppat.1002111.
14. Wahala WM, Silva AM. 2011. The human antibody response to dengue virus infection. Viruses 3:2374-2395.
15. Beasley DW, Barrett AD. 2002. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76:13097-13100.
16. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
17. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 6:e1000823. doi:10.1371/journal.ppat.1000823.
18. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84:9227-9239.
19. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS. 2010. Genotype specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 84:10630-10643.
20. Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS. 19 June 2013. Functional analysis of antibodies against Dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J. Virol. doi:10.1128/JVI.01314-13.
21. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. 2009. Dengue virus neutralization by human immune sera:role of envelope protein domain III-reactive antibody. Virology 392:103-113.
22. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. 2012. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429:12-20.
23. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U.S.A. 109:7439-7444.
24. Li PC, Liao MY, Cheng PC, Liang JJ, Liu IJ, Chiu CY, Lin YL, Chang GJ, Wu HC. 2012. Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl. Trop. Dis. 6:e1636. doi:10.1371/journal.pntd.0001636.
25. Zou G, Kukkaro P, Lok SM, Ng JK, Tan GK, Hanson BJ, Alonso S, MacAry PA, Shi PY. 2012. Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1. Antiviral Res. 95:216-223.
26. Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S. 2013. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J. Virol. 87:52-66.
27. Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, Diamond MS, Harris E. 2013. Therapeutic efficacy of antibodies lacking FcγR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. PLoS Pathog. 9:e1003157. doi:10.1371/journal.ppat.1003157.
28. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE, Jr. 2013. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis. 207:1898-1908.
29. Morens DM, Halstead SB, Marchette NJ. 1987. Profiles of antibodydependent enhancement of dengue virus type 2 infection. Microb. Pathog. 3:231-237.
30. Midgley CM, Flanagan A, Tran HB, Dejnirattisai W, Chawansuntati K, Jumnainsong A, Wongwiwat W, Duangchinda T, Mongkolsapaya J, Grimes JM, Screaton GR. 2012. Structural analysis of a dengue crossreactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J. Immunol. 188:4971-4979.
31. Kimura R, Hotta S. 1944. Studies on dengue fever (VI). On the inoculation of dengue virus into mice. Nippon Igaku 3379:629-633. (In Japanese.)
32. Hotta S, Kimura R. 1952. Experimental studies on dengue. I. Isolation, identification and modification of the virus. J. Infect. Dis. 90:1-9.
33. Konishi E, Fujii A. 2002. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20:1058-1067.
34. Konishi E, Yamaoka M, Kurane I, Mason PW. 2000. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18:1133-1139.
35. Yamanaka A, Kosugi S, Konishi E. 2008. Infection-enhancing and-neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J. Virol. 82:927-937.
36. Konishi E, Kosugi S, Imoto J. 2006. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24:2200-2207.
37. Konishi E, Sakai Y, Kitai Y, Yamanaka A. 2009. Prevalence of antibodies to Japanese encephalitis virus among inhabitants in Java Island, Indonesia, with a small pig population. Am. J. Trop. Med. Hyg. 80:856-861.
38. Konishi E, Suzuki T. 2002. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations:evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 21:98-107.
39. Konishi E, Terazawa A, Fujii A. 2003. Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Vaccine 21:3713-3720.
40. Henchal EA, Gentry MK, McCown JM, Brandt WE. 1982. Dengue virus-specific and Flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am. J. Trop. Med. Hyg. 31:830-836.
41. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS. 2000. Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 6:816-820.
42. Halstead SB, O'Rourke EJ. 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146:201-217.
43. Konishi E, Tabuchi Y, Yamanaka A. 2010. A simple assay system for infection-enhancing and-neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J. Virol. Methods 163:360-367.
44. Littaua R, Kurane I, Ennis FA. 1990. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144:3183-3186.
45. Jin X, Block OT, Rose R, Schlesinger J. 2009. Dengue vaccine development and dengue viral neutralization and enhancement assays. Antivir. Ther. 14:739-749.
46. Hall RA, Broom AK, Hartnett AC, Howard MJ, Mackenzie JS. 1995. Immunodominant epitopes on the NS1 protein of MVE and KUN viruses serve as targets for a blocking ELISA to detect virusspecific antibodies in sentinel animal serum. J. Virol. Methods 51:201-210.
47. Blitvich BJ, Marlenee NL, Hall RA, Calisher CH, Bowen RA, Roehrig JT, Komar N, Langevin SA, Beaty BJ. 2003. Epitope-blocking enzymelinked immunosorbent assays for the detection of serum antibodies to West Nile virus in multiple avian species. J. Clin. Microbiol. 41:1041-1047.
48. Kitai Y, Shoda M, Kondo T, Konishi E. 2007. Epitope-blocking enzymelinked immunosorbent assay to differentiate West Nile virus from Japanese encephalitis virus infections in equine sera. Clin. Vaccine Immunol. 14:1024-1031.
49. Yamanaka A, Tabuchi Y, Mulyatno KC, Susilowati H, Hendrianto E, Soegijanto S, Konishi E. 2012. Dengue virus infection-enhancing and neutralizing antibody balance in children of the Philippines and Indonesia. Microbes Infect. 14:1152-1159.
50. Falconar AK. 1999. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch. Virol. 144:2313-2330.
51. Serafin IL, Aaskov JG. 2001. Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies. Arch. Virol. 146:2469-2479.
52. Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, Johnson S, Diamond MS, Lai CJ, Rose RC, Jin X, Schlesinger JJ. 2009. Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 394:175-182.
53. Wightman J, Roberson MS, Lamkin TJ, Varvayanis S, Yen A. 2002. Retinoic acid-induced growth arrest and differentiation:retinoic acid upregulates CD32 (Fc gammaRII) expression, the ectopic expression of which retards the cell cycle. Mol. Cancer Ther. 1:493-506.
54. Rebuffat SA, Morin M, Nguyen B, Castex F, Robert B, Péraldi-Roux S. 2010. Human recombinant anti-thyroperoxidase autoantibodies:in vitro cytotoxic activity on papillary thyroid cancer expressing TPO. Br. J. Cancer 102:852-861.
55. Cohen-Solal JF, Cassard L, Fournier EM, Loncar SM, Fridman WH, Sautès-Fridman C. 2010. Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity. Dermatol. Res. Pract. 2010:657406.
56. Bruhns P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640-5649.
57. Hamilton RG. 1987. Human IgG subclass measurements in the clinical laboratory. Clin. Chem. 33:1707-1725.
58. Nussenzweig RS, Merryman C, Benacerraf B. 1964. Electrophoretic separation and properties of mouse antihapten antibodies involved in passive cutaneous anaphylaxis and passive hemolysis. J. Exp. Med. 120: 315-328.
59. Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. 2009. Vaccine-induced enhancement of viral infections. Vaccine 27: 505-512.
60. Heinz FX, Stiasny K. 2012. Flaviviruses and flavivirus vaccines. Vaccine 30:4301-4306.
61. Hughes HR, Crill WD, Chang GJ. 2012. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibodydependent enhancement. Virol. J. 9:115. doi:10.1186/1743-422X-9-115.
62. Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ. 2012. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front. Immunol. 3:334.
63. Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremon DH, Pierson TC, Diamond MS. 2007. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclassspecific manner. Cell Host Microbe 2:417-426.